[en] Selective progesterone receptor modulators (SPRM) represent a new class of synthetic steroids, which can interact with the progesterone receptor (PR) and can exert agonist, antagonist or mixed effects on various progesterone target tissues in vivo. This review evaluates the actual and potential usefulness of SPRMs in gynaecology
Disciplines :
Reproductive medicine (gynecology, andrology, obstetrics)
Author, co-author :
Pintiaux, Axelle ; Centre Hospitalier Universitaire de Liège - CHU > Gynécologie-Obstétrique CHR
Chabbert-Buffet, N.
Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique - Labo de biologie des tumeurs et du développement
Language :
English
Title :
Gynaecological uses of a new class of steroids: the selective progesterone receptor modulators
Chwalisz K, Perez MC, DeManno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005;26:423-438.
Philibert D. RU38486: an original multifacted antihormone in vivo. In: Agarwal M, editor. Adrenal Steroid Antagonism. Berlin: Walter de Gruyter and Co.; 1984. pp 77-101.
Neef G, Beier S, Elger W, Henderson D, Wiechert R. New steroids with anti-progestational and anti-glucocorticoid activities. Steroids 1984;44:349-372.
Kloosterboer HJ, Deckers GH, Van de Heuvel MJ, Loozen HJ. Screening of anti-progestagens by receptor studies and bioassays. J Steroid Biochem 1988;31:567-571.
Chabbert-Buffet N, Meduri G, Bouchard P, Spitz E. Selective progesterone receptor modulator and progesterone antagonist: mechanism of action and clinical application. Hum Reprod Update 2005;11:293-307.
Csapo A. Progesterone block. Am J Anat 1956;98:273-291.
Padykula HA. Regeneration in the primate uterus: the role of stem cells. Ann NY Acad Sci 1991;622:47-56.
Brandon DD, Bethea CL, Strawn EY, Novy MJ, Burry KA, Harrington MS, Erickson TE, Warner C, Keenan EJ, Clinton GM. Progesterone receptor messenger ribonucleic acid and protein are over expressed in human uterine leiomyomas. Am J Obstet Gynecol 1993;169:78-85.
Nisolle M, Gillerot S, Casanas-Roux F, Squifflet J, Berliere M, Donnez J. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum Reprod 1999;14:2844-2850.
Kawaguchi K, Fujii S, Konishi I, Nanbu Y, Nonogaki H, Mori T. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 1989;160:637-641.
Lundstrom E, Wilczek B, von Palffy Z, Soderqvist G, von Schoultz B. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol 1999;181:348-352.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
Beral V. Breast cancer and hormone-replacement therapy in the million women study. Lancet 2003;362:419-427.
Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 2006;314:1467-1470.
Mahajan DK, London SN. Mifepristone (RU 486): a review. Fertil Steril 1997;86:967-976.
Hermann WL, Schlindler AM, Wyss R, Bischoff P. Effects of anti-progesterone RU 486 in early pregnancy and during the menstrual cycle. In: Beaulieu EE, Siegel S, editors. The Antiprogestin Steroid RU 486 and Human Fertility Control. New York: Plenum; 1985. pp 259-262.
Schreiber C, Creinin M. Mifepristone in abortion care. Semin Reprod Med 2005;23:82-91.
Tang OS, Ho PC. Clinical applications of mifepristone. Gynecol Endocrinol 2006;22:655-659.
Kovacs L, Sas M, Resch BA, Ugocsai G, Swahn ML, Bygdeman M, Rowe PJ. Termination of very early pregnancy by RU 486, an anti-progestational compound. Contraception 1984;29:399-410.
Shoupe D, Mishell DR Jr, Brenner PF, Spitz IM. Pregnancy termination with a high and medium dosage regimen of RU- 486. Contraception 1986;33:455-461.
Peyron R, Aubény E, Targosz V, Silvestre L, Renault M, Elkik F, Leclerc P, Ulmann A, Baulieu EE. Early termination on pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med 1993;328:1509-1513.
Aubeny E, Peyron R, Turpin CL, Renault M, Targosz V, Silvestre L, Ulmann A, Baulieu EE. Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone (RU 486) and increasing doses of misoprostol. Int J Fertil Menopausal Stud 1995;40 (Suppl 2):85-91.
Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med 1998;338:1241-1247.
Aubeny E. A two-stage increase in the dose of misoprostol improves the efficacy of medical abortion with mifepristone and prostaglandins (letter). Eur J Contracept Reprod Health Care 2001;6:54-55.
World Health Organization Task Force on Post-ovulatory Methods for Fertility Regulation. Termination of pregnancy with reduced doses of mifepristone. BMJ 1993; 307:532-537.
McKinley C, Thong KJ, Baird DT. The effect of dose of mifepristone and gestation on efficacy of medical abortion with mifepristone and misoprostol. Hum Reprod 1993; 8:1502-1505.
World Health Organization Task Force on Post-ovulatory Methods for Fertility Regulation. Comparison of two-doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. BJOG 2000;107:524-530.
Schaff EA, Eisinger SH, Stadalius LS, Franks P, Gore BZ, Poppema S. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion. Contraception 1999;59:1-6.
Ashok P, Penney G, Flett G, Templeton A. An effective regimen for early medical abortion: a report of 2000 consecutive cases. Hum Reprod 1998;13:2962-2965.
Schaff EA, Fielding SL, Eisinger SH, Stadalius LS, Fuller L. Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days. Contraception 2000; 61:41-46.
